Vaporization as a Smokeless Cannabis Delivery System
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00241592 |
Recruitment Status :
Completed
First Posted : October 19, 2005
Last Update Posted : June 14, 2007
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Healthy Volunteers | Drug: Cannabis | Phase 1 |
Study Type : | Interventional (Clinical Trial) |
Enrollment : | 18 participants |
Allocation: | Randomized |
Intervention Model: | Crossover Assignment |
Masking: | Double |
Primary Purpose: | Treatment |
Official Title: | Vaporization as a Smokeless Cannabis Delivery System: A Pilot Study |
Study Start Date : | August 2004 |
Study Completion Date : | May 2005 |
- To assess the delivery of cannabinoids and metabolites by way of vaporization and to compare plasma levels to those obtained from smoking an identical amount of marijuana from a cigarette.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 21 Years to 45 Years (Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Age 21-45 years Current history use of marijuana. Subjects must have smoked marijuana within the past 30 days but an amount totaling less than 10 marijuana cigarettes or the equivalent.
All men and women in this study must agree to use adequate birth control during the study. Acceptable barrier birth control methods are a male condom, female condom, diaphragm, or intra-uterine (IUD).
All women of reproductive potential (who have not reached menopause or undergone hysterectomy, oophorectomy,or tubal ligation) must have a negative urine B-HCG pregnancy test performed 48 hours before initiating the protocol-specified medication.
Able to understand and follow the instructions of the investigator and research personnel.
Able and willing to provide informed consent.
Exclusion Criteria:
- Severe coronary artery disease, uncontrolled hypertension, cardiac ventricular conduction abnormalities, or orthostatic mean blood pressure drop greater than 24mm/Hg, severe chronic obstructive pulmonary disease.
History of renal or hepatic failure. Evidence of hepatic, hematological or renal dysfunction based on judgement of physician.
Active substance abuse. Marijuana dependence as defined in DSM-IV code#304.30. Any psychiatric dysfunction that would, in the opinion of the study investigator, interfere with a participant's ability to comply with the study protocol.
Use of tobacco within the past 30 days. Subjects taking medications which may be vulnerable to drug-drug interactions such as those metabolized by the cytochrome P450 enzyme system.
Blood donation in the past 30 days. Use of smoked marijuana within 48 hours of GCRC admission. Women who are pregnant or breast-feeding may not take part in this study. Unable to read or speak English.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00241592
United States, California | |
UCSF Community Consortium | |
San Francisco, California, United States, 94110 |
Principal Investigator: | Donald I Abrams, M.D. | UCSF Community Consortium |
Publications of Results:
ClinicalTrials.gov Identifier: | NCT00241592 |
Other Study ID Numbers: |
C03-SF-115 CC#062 CHR# 105-22909-02 PR# 0334 |
First Posted: | October 19, 2005 Key Record Dates |
Last Update Posted: | June 14, 2007 |
Last Verified: | June 2007 |
Cannabis Marijuana Vaporization Volcano THC |
Marijuana Abuse Substance-Related Disorders Chemically-Induced Disorders Mental Disorders |